ACAD.OQ - ACADIA Pharmaceuticals Inc
Guggenheim Securities LLC
ACAD - FY25; Strong Execution and Robust 2026 Guidance Set the Stage for Pivotal Remlifanserin ADP Data in 2H26; Mgmt Also Provided Expectations For 2028 Revenues
公司
ACAD.OQ
日期
2026-02-26
分析师
Mr. Yatin Suneja
页数
8 页
需要登录
请登录后购买研报或生成音频内容。